Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 942-066-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 2014-2015
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study, for read-across justification refer to IUCLID section 13.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 015
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.31 (Prenatal Developmental Toxicity Study)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3700 (Prenatal Developmental Toxicity Study)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- XPB 115
- IUPAC Name:
- XPB 115
- Reference substance name:
- Hexanedioic acid, bis(2-propylheptyl) ester
- IUPAC Name:
- Hexanedioic acid, bis(2-propylheptyl) ester
- Reference substance name:
- Bis(2-propylheptyl) hexanedioate
- EC Number:
- 940-510-9
- Molecular formula:
- C26 H50 O4
- IUPAC Name:
- Bis(2-propylheptyl) hexanedioate
- Test material form:
- other: liquid
- Details on test material:
- refer to confidential details on test material
Constituent 1
Constituent 2
Constituent 3
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Laboratories B.V., Venray, The Netherlands
- Age at study initiation: Age at delivery: Females were approximately 10 to 14 weeks.
- Weight at study initiation: 17.6 - 22.2 g (group means)
- Fasting period before study: no
- Housing: individually housed in Macrolon plastic cages (MIII type)
- Diet (e.g. ad libitum):ad libitum
- Water (e.g. ad libitum):ad libitum
- Acclimation period: at least 4 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18 - 24 °C
- Humidity (%): 40 - 70%
- Air changes (per hr): at least 10
- Photoperiod (hrs dark / hrs light): 12-hour light/12-hour dark cycle
IN-LIFE DATES: From: 25 December 2014 To: 14 January 2015
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: Formulations (w/w) were prepared daily within 5 hours prior to dosing and
were homogenized to a visually acceptable level
VEHICLE
- Justification for use and choice of vehicle (if other than water): Based on trial formulations - Analytical verification of doses or concentrations:
- yes
- Details on mating procedure:
Untreated females were mated at the supplier, and were at Day 0, 1 or 2
post-coitum on arrival at the test facility (Day 0 post-coitum was the day
of successful mating; confirmed by vaginal plug).- Duration of treatment / exposure:
- From Day 6 to Day 20 post-coitum, inclusive
- Frequency of treatment:
- once daily
- Duration of test:
- treatment from Day 6 to Day 20 post-coitum, inclusive; necropsy on day 21 post-coitum
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 60, 200, 600 mg/kg bw/d
Basis:
actual ingested
- No. of animals per sex per dose:
- 22 females per dose group
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: prestudy
- Rationale for animal assignment: random
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least twice daily
- Cage side observations checked in table [No.?] were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations:Days 3, 6, 9, 12, 15, 18 and 21 post-coitum.
FOOD CONSUMPTION: Yes
Days 3-6, 6-9, 9-12, 12-15, 15-18 and 18-21 post-coitum.
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day # 21
- Organs examined: organ weights: (gravid) uterus, liver, spleen, necrospy: Gross lesions, ovary and uterine horn, spleen, liver, Identification marks - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: number and distribution of live and dead fetuses, weight of each fetus, sex of each fetus from the ano-genital distance (during necropsy) and also from gonadal inspections (during further fetal examination), weight of each placenta. - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes: all per litter
- Skeletal examinations: Yes: all per litter
- Head examinations: Yes: half per litter - Statistics:
- The following statistical methods were used to analyze the data:
- If the variables could be assumed to follow a normal distribution, the Dunnett-test (many-toone
t-test) based on a pooled variance estimate was applied for the comparison of the treated
groups and the control group.
- The Steel-test (many-to-one rank test) was applied if the data could not be assumed to follow
a normal distribution.
- The Fisher Exact-test was applied to frequency data.
- The Mann Whitney test was used to compare mean litter proportions (percent of litter) of the
number of viable and dead fetuses, early and late resorptions, total resorptions, pre- and postimplantation
loss, and sex distribution.
- Mean litter proportions (percent per litter) of total fetal malformations and developmental variations
(external, visceral and skeletal), and each particular external, visceral and skeletal malformation or
variation were subjected to the Kruskal-Wallis nonparametric ANOVA test to determine
intergroup differences. If the ANOVA revealed statistically significant (p<0.05) intergroup variance,
Dunn’s test was used to compare the compound-treated groups to the control group.
All tests were two-sided and in all cases p < 0.05 was accepted as the lowest level of significance.
Group means were calculated for continuous data and medians were calculated for discrete data
(scores) in the summary tables. Test statistics were calculated on the basis of exact values for means
and pooled variances. Individual values, means and standard deviations might be rounded off before
printing. Therefore, two groups might display the same printed means for a given parameter, yet
display different test statistics values.
No statistics were applied for data on maternal survival, pregnancy status, group mean numbers of
dead fetuses, early and late resorptions, and pre- and post-implantation loss.
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
-increased absolute and/or relative liver weights at 200 and 600 mg/kg bw/d
- lower total protein and increased urea at 600 mg/kg bw/d
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 200 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
- Dose descriptor:
- NOAEL
- Effect level:
- 200 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:yes
Details on embryotoxic / teratogenic effects:
At 600 mg/kg bw/day, reduced fetal body weights were noted (approximately 8% lower than control levels, combined for both sexes) along with a correspondingly higher incidence of reduced ossification parameters. An increase in unossified metacarpal(s) and/or metatarsal(s) was the most pronounced effect and an increase in reduced ossification of the skull also occurred, but to a lesser degree.
An increase in skeletal variations at 600 mg/kg bw/day that were not body weight dependent included increased incidence of 14th rudimentary rib(s), 14th full rib(s), 7th cervical rudimentary rib(s), and caudal shift of the pelvic girdle.
These effects indicate a generalized delay in ossification, a well documented effect often associated with maternal toxicity of various different mechanisms and/or affected homeostasis. In the present study, increased maternal liver weights and changes in clinical chemistry parameters indicate an adversely disturbed liver homeostasis. In addition, a generalized delay in ossification is expected to be readily repairable during early postnatal development and is therefore not considered as specific developmental toxicity.
There were no treatment-related effects on fetal external, visceral or skeletal malformations, on
external and visceral variations and on litter size, male:female ratios and placenta weights up to and including 600mg/kg bw/day. No developmental toxicity was observed in the 60 and 200 mg/kg bw/day groups.
Effect levels (fetuses)
- Dose descriptor:
- NOAEL
- Effect level:
- > 600 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: teratogenicity
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Any other information on results incl. tables
At 600 mg/kg bw/day, reduced fetal body weights were noted (approximately 8% lower than control levels, combined for both sexes) along with a correspondingly higher incidence of reduced ossification parameters. An increase in unossified metacarpal(s) and/or metatarsal(s) was the most pronounced effect and an increase in reduced ossification of the skull also occurred, but to a lesser degree. An increase in skeletal variations at 600 mg/kg bw/day that were not body weight dependent included increased incidence of 14th rudimentary rib(s), 14th full rib(s), 7th cervical rudimentary rib(s), and caudal shift of the pelvic girdle. These effects indicate a generalized delay in ossification, a well documented effect often associated with maternal toxicity of various different mechanisms and/or affected homeostasis. In the present study, increased maternal liver weights and changes in clinical chemistry parameters indicate an adversely disturbed liver homeostasis. In addition, a generalized delay in ossification is expected to be readily repairable during early postnatal development and is therefore not considered as specific developmental toxicity. There were no treatment-related effects on fetal external, visceral or skeletal malformations, on external and visceral variations and on litter size, male:female ratios and placenta weights up to and including 600mg/kg bw/day. No developmental toxicity was observed in the 60 and 200 mg/kg bw/day groups.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.